Novo Nordisk A/S (NVO) Rating Increased to Hold at ValuEngine

ValuEngine upgraded shares of Novo Nordisk A/S (NYSE:NVO) from a sell rating to a hold rating in a research report released on Saturday.

NVO has been the topic of a number of other reports. Deutsche Bank restated a buy rating on shares of Novo Nordisk A/S in a research report on Thursday, October 4th. Guggenheim started coverage on shares of Novo Nordisk A/S in a research report on Monday, October 8th. They issued a buy rating on the stock. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a market perform rating to an outperform rating in a research report on Monday, July 2nd. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a sell rating to a hold rating in a research report on Tuesday, July 31st. Finally, Kepler Capital Markets restated a hold rating on shares of Novo Nordisk A/S in a research report on Thursday, October 18th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the stock. Novo Nordisk A/S presently has a consensus rating of Hold and an average price target of $64.00.

NYSE NVO opened at $42.57 on Friday. Novo Nordisk A/S has a 12 month low of $41.23 and a 12 month high of $58.37. The firm has a market cap of $103.58 billion, a price-to-earnings ratio of 18.19, a P/E/G ratio of 2.22 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, August 8th. The company reported $0.68 EPS for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.04. Novo Nordisk A/S had a net margin of 35.95% and a return on equity of 83.32%. The firm had revenue of $4.39 billion for the quarter, compared to the consensus estimate of $4.33 billion. On average, equities research analysts predict that Novo Nordisk A/S will post 2.47 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Chicago Partners Investment Group LLC lifted its position in Novo Nordisk A/S by 762.5% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 3,131 shares of the company’s stock valued at $144,000 after purchasing an additional 2,768 shares during the last quarter. Legacy Financial Advisors Inc. lifted its position in Novo Nordisk A/S by 527.8% in the 3rd quarter. Legacy Financial Advisors Inc. now owns 3,886 shares of the company’s stock valued at $183,000 after purchasing an additional 3,267 shares during the last quarter. Schroder Investment Management Group bought a new stake in Novo Nordisk A/S in the 2nd quarter valued at about $182,000. Stevens Capital Management LP bought a new stake in Novo Nordisk A/S in the 2nd quarter valued at about $202,000. Finally, Verition Fund Management LLC bought a new stake in Novo Nordisk A/S in the 1st quarter valued at about $217,000. Institutional investors own 6.70% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

Recommended Story: Book Value Per Share – BVPS

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply